



# MEDCO FORUM<sup>®</sup>

PRESENTING INNOVATIVE PRODUCTS & SERVICES TO HEALTHCARE PROFESSIONALS

## Medco Forum Presents: Aerocrine's NIOX MINO<sup>®</sup>

On September 1, 2011, the American Thoracic Society (ATS) released an Official Clinical Practice Guideline that provides recommendations as to how fractional exhaled nitric oxide (FENO) measurements should be used and interpreted in treating patients with airways disease, notably asthma.



Measuring FENO is easy to do and it provides an objective value immediately. Dr. Lim remarks that both high and low values are clinically significant and the information will help fine-tune treatment. "Not only does the FENO value tell you whether there is inflammation that would be compatible with asthma, it also helps you identify those patients who will (or will not) respond to inhaled steroids or, if already on inhaled steroids, to recognize if a patient's dose needs to be adjusted. If a patient comes in with complaints of frequent asthma attacks and it turns out that the FENO measurement is still high


in spite of treatment, I can see that the patient is not receiving enough of the inhaled steroid and adjust the dose accordingly."

Traditional tools for diagnosing and monitoring asthma – the history, physical examination, lung function tests, and quality of life instruments – are not appropriate proxies for airway inflammation. Exhaled nitric oxide is such a proxy, and can be measured with simple to use, relatively inexpensive equipment.

"Successful management of airway inflammation is a key factor in attaining and sustaining asthma control," says Peter B. Boggs, MD, a specialist in Allergy, Asthma, and Immunology (Shreveport, LA). "The ability to measure FENO and gain insight into the status of the underlying airway inflammation in a patient, in context with the history, physical, lung function tests, and the quality of life indicator, is a paradigm change in how we help people manage their asthma." Dr. Boggs goes on to say, "In the past, we've assumed that someone is in 'good control' when the traditional tools indicate such, but we now know this can be quite wrong."

The NIOX MINO<sup>®</sup> airway inflammation monitor pioneered and manufactured by Aerocrine, is the only FDA cleared FENO device currently marketed in the US. It is a maintenance-free device available for measuring FENO. The NIOX MINO<sup>®</sup>, a compact, handheld device, provides a non-invasive, quantitative, cost-effective and safe measurement of airway inflammation status and all values are quality assured. With more than 4 million successful tests performed worldwide, the NIOX MINO<sup>®</sup> is the most widely used device for measuring FENO in clinical practice and clinical research. Reliability has been documented extensively in numerous peer-reviewed clinical papers. The device provides immediate results and is easy to use for both physicians and their patients. Inflammation measurement with NIOX MINO<sup>®</sup>, offers personalized asthma management that can improve the treatment and care of patients.





***For more information about the NIOX MINO<sup>®</sup>,  
please call 1-866-275-6469,  
visit our website at [www.aerocrine.com](http://www.aerocrine.com),  
or speak to a representative at the ACAAI Conference,  
Booth # 604.***